$200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value Principal balance reduced to approximately $186.2 million NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company's Board of Directors had authorized a repurch ...

NASHVILLE, Tenn., July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2024 on Tuesday, August 6, 2024 after U.S. markets close. Conference Call Information Date: Tuesday, August 6, 2024 Time: 5:00 p.m. ET Dial-in numbers: 1-800-717-1738 (U.S.), 1-646-307-1865 (International) Confirmation code:Request the " ...

CryoPort expects revenues to improve as the year goes on. Revenues from the company's Life Sciences Products group are likely to drive growth. Moreover, it seems that investors are bullish on the fact that the Schall Law Firm, a national shareholder rights litigation firm, is investigating claims regarding violations of the securities laws by CYRX. This development might have led to the northward movement of the CYRX stock following losses over the past few weeks. The stock currently carries a Zacks Rank #2 ...

Partnership Will Provide Cell and Gene Therapy Industry with Fully Integrated Logistics and Manufacturing Services for Regenerative Medicine Products NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and Minaris Regenerative Medicine Co., Ltd. ("Minaris"), a global contract development and manufacturing organization for cell and gene therapies, today announced a strategic partnershi ...

LOS ANGELES, June 5, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ: CYRX) for violations of the securities laws. CONTACT: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] www ...

Paul, our goals have not changed. Our goals are 55% to 60% gross margin and 30% adjusted EBITDA. Our goals are not changed, and we do examine them often. So that's the metrics that you should be looking for from us. Operator Thank you for taking our questions. So, can you help us better understand the weakness in biologic services in 1Q, was it because of lower volume? And how about the visibility and confidence in 2Q and beyond? And I have follow-up. Thomas Heinzen Sorry, can you repeat the question, guys? ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

®2024 CRYOPORT, INC. Condensed Consolidated Statements of Operations (unaudited) | 16 March 31, $ (18,895) $ 46 | 17 Cryoport Enabling the Future of Medicine Increased by 21 trials (net) over Q1 2023 | --- | --- | --- | --- | --- | --- | --- | --- | |---------|-----------|-----------|-----------|-----------|-----------|-----------|-----------| | 350 | 609 | 652 | 675 | 600 | 609 | 652 | 675 | | 300 | | | | 500 | | | | | 250 | | | | 400 | | | | | 200 | | | | 300 | | | | | 150 | | | | 200 | | | | | 100 | | | ...

Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results NASHVILLE, Tennessee, May 7, 2024, - Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024. Jerrell Shelton, CEO of Cryoport, commented, "For the first quarter, we continued to experience a difficult environment globally. Our quarterly results were disappointing, particularly for our Life Sciences Products. Ho ...

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX), a global leader in supply chain solutions for cell & gene therapies, today announced that the Company will report financial results for the first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport First Quarter 2024 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be i ...